Clinical Trial Detail

NCT ID NCT01215136
Title First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Hoosier Cancer Research Network
Indications

urethra transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Everolimus

Paclitaxel

Age Groups: adult

No variant requirements are available.